We previously showed that patients with PCa and a low level PSA (< 3.5 ng / mL) tend to be in more advanced stages than those with PSA levels between 3.5 ng / mL and 10 ng / mL and that PSA could no longer be used as a prognostic factor in patients with PCa and extremely high PSA levels (> 100 ng / mL) (3, 4). The gene discussed is KLK3; the disease is posterior cortical atrophy.